

Essentials of Diagnostic Pathology
Series Editor: Farid Moinfar

Christine Beham-Schmid
Annette Schmitt-Graeff

Bone Marrow Biopsy Pathology

A Practical Guide

Essentials of Diagnostic Pathology

More information about this series at: <http://www.springer.com/series/8171>

Christine Beham-Schmid
Annette Schmitt-Graeff

Bone Marrow Biopsy Pathology

A Practical Guide

 Springer

Christine Beham-Schmid
Institute of Pathology
Medical University Graz
Graz
Austria

Annette Schmitt-Graeff
Albert-Ludwigs-University of Freiburg
Freiburg
Germany

Series Editor

Farid Moinfar
Department of Pathology, Ordensklinikum Linz/Hospital of the Sisters of Charity
Department of Pathology, Medical University of Graz
Graz, Austria

ISSN 2194-6256 ISSN 2194-6264 (electronic)
Essentials of Diagnostic Pathology
ISBN 978-3-662-60307-9 ISBN 978-3-662-60309-3 (eBook)
<https://doi.org/10.1007/978-3-662-60309-3>

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer-Verlag GmbH, DE part of Springer Nature.
The registered company address is: Heidelberger Platz 3, 14197 Berlin, Germany

Preface

When I (C.B-S) was asked by Prof. F. Moinfar to write a book on bone marrow pathology, I was hesitant in view of the abundance of excellent textbooks on this topic. However, the fact that this book should be intended as a practical guide dominated rather by illustrations than by text, and the promise of Prof. Annette Schmitt-Graeff to act as a coauthor, at least encouraged me to start this project.

As a young internship doctor in the small public hospital in Oberndorf/Salzburg, I (C.B-S) was stimulated by Primarius Dr. K. Mittermayer to have a look on bone marrow aspirates. This resulted in my interest in hematology, which was deepened when I consecutively started a training in pathology with focus on hematopathology at the Institute of Pathology, Faculty of Medicine, University of Graz. During this time, I received intensive training in bone marrow biopsy pathology in Munich (Prof. Burkhardt) and Tel Aviv (Bertha Frisch) and in lymphoma diagnostics in London (P.G. Isaacson). Up to now, I have seen ten thousands of bone marrow biopsies and gained a lot of experience. Since the knowledge of clinical data is essential for exact pathohistological diagnosis of bone marrow biopsies, a close cooperation with the clinical colleagues is mandatory.

My (A.S-G) enthusiasm for bone marrow (BM) diagnostics dates back to my residency in hematology/oncology at the Departments of Internal Medicine, University Hospitals of Cologne and Essen, Germany. I was keen on evaluating blood and BM cytology. I also realized the impact of BM and lymph node biopsies on therapeutic strategies for our patients suffering from myeloid or lymphoproliferative neoplasms. This appreciation was the rationale to pursue a residency and a fellowship in anatomical pathology at the University Hospital Düsseldorf, Germany, where I established histologic BM assessment. My research activities were on the cytoskeleton including BM stroma with Prof. Dr. Dr. h.c. Giulio Gabbiani, University Hospital Geneva, Switzerland, where I assumed the position as consultant. There and at the Berlin Reference Center for Lymph Node Pathology of Prof. Dr. Dr. h.c. Harald Stein I was principally in charge of BM pathology including supervising residents in this field.

Later, I joined the faculty at the Medical Center, University Freiburg, Germany, where I was appointed Professor of Hematopathology and GI Pathology. My activities were focused on integrating morphological, immunophenotypic, and molecular aspects of hematological neoplasms and primary immunodeficiency disorders with the late Prof. Dr. Paul Fisch in close clinico-pathologic cooperation.

As previous president of the German Division of the IAP (GDIAP) and actual member of the General IAP and GDIAP Education committees, I have taught and directed numerous hematopathology courses of the IAP nationally and internationally. In the context of my active involvement in education and teaching, I am delighted to contribute to this textbook with a mix of basic information and challenging diagnostic cases.

This book is intended as a practical guide in the complex field of bone marrow pathology. We hope it will turn out helpful in the daily diagnostic work.

June 2020
Graz, Austria
Freiburg, Germany

Christine Beham-Schmid
Annette Schmitt-Graeff

Acknowledgments

I would like to thank my coauthor and friend Annette Schmitt-Graeff, without her support, my own contributions for this book would not have been possible.

Moreover, I am deeply indebted to Prof. Farid Moinfar for giving me the opportunity to write this book with my coauthor.

My special acknowledgment is also attributed to my teachers in hematology and hematopathology Prim. Dr. K. Mittermayer, Oberndorf/Salzburg, Prof. Dr. R. Burkhardt, Munich/Germany, Prof. Dr. B. Frisch, Tel Aviv/Israel, Prof. P.G. Isaacson, London/G.B., and Prof. Dr. J. Thiele, Cologne/Germany.

In addition, I would like to recognize the excellent work of the team of the laboratory of hematopathology and the photographers, Institute of Pathology, Medical University of Graz, Austria.

Last but not least, I am most grateful to my husband Alfred and my son Clemens for their never-ending patience and support during this project.

Christine Beham-Schmid

First, I would like to acknowledge the great dedication of my coauthor Prof. Dr. Christine Beham-Schmid, Graz, and the series Editor Prof. Dr. Farid Moinfar, Linz, Austria, to the project of our book.

I express my deep appreciation to many experts who inspired me with their devotion to hematopathology and hematology. In particular, I want to mention Prof. Dr. Dr.hc Harald Stein, Berlin, and Prof. Dr. Juergen Thiele, Cologne/Hannover, Germany, and Prof. Dr. Kristin Henry, London, G.B. Special thanks go to Prof. Dr. Rüdiger Hehlmann who founded the European LeukemiaNet (ELN). I would also like to acknowledge Prof. Dr. Attilio Orazi, El Paso, and Prof. Dr. Daniel A. Arber, Chicago, USA, for their exciting investigations and teaching in hematopathology.

I am especially indebted to Prof. Dr. Robert Zeiser, Dr. Dietmar Pfeifer, Dr. Milena Pantic, and Dr. Justina Rawluk, Department of Hematology and Oncology, Medical Center, University Freiburg, Germany, for their support and helpful contribution to molecular analyses, cytogenetics, and cytology of myeloid neoplasms.

Lastly, I would like to thank my mother Margret Gräff, my husband Eberhard Schmitt, our son Rafael J. P. Schmitt, and my daughter-in-law Zeldä Othenin for their patience and love.

Annette Schmitt-Graeff

Contents

1 Normal Bone Marrow	1
Christine Beham-Schmid	
1.1 Introduction	1
1.1.1 Bone Components	2
1.2 Cellularity of the Marrow	6
1.2.1 Topography	8
1.3 Cellular Components of the Bone Marrow	10
1.3.1 Hematopoiesis	10
1.3.2 Erythrocytopoiesis	10
1.3.3 Granulocytopoiesis	12
1.3.4 Monocytopoiesis and Macrophages	14
1.3.5 Megakaryocytopoiesis	16
1.3.6 Lymphocytes	19
1.3.7 Plasma Cells	22
1.3.8 Mast Cells	22
1.3.9 Bone Marrow Stroma	24
References	26
2 Non-neoplastic Conditions with Quantitative and Qualitative Changes in Hematopoiesis	27
Christine Beham-Schmid	
2.1 Common Non-neoplastic Erythroid Lineage Disorders	27
2.1.1 Common Examples of Anemia	27
2.2 Acquired Anemias	28
2.2.1 Anemia of Chronic Disease (ACD)	28
2.2.1.1 Caution	28
2.2.2 Iron Deficiency Anemias (IDA)	30
2.2.2.1 Caution	30
2.2.3 Megaloblastic Anemias	32
2.2.3.1 Caution	32
2.2.4 Hemolytic Anemia	34
2.2.4.1 Caution	34
2.2.5 Aplastic Anemia	36
2.2.5.1 Caution	38
2.3 Bone Marrow Biopsy in Collagen Vascular Diseases (CVD), Especially in Systemic Lupus Erythematosus (SLE)	40
2.3.1 Caution	42
2.4 Bone Marrow Involvement in Castleman’s Disease	44
2.4.1 Caution	44
2.5 Non-neoplastic Conditions with Quantitative and Qualitative Changes in Granulopoiesis	49
2.5.1 Severe (Acquired) Neutropenia	49
2.5.1.1 Caution	49

2.6	Kostmann Disease (Infantile Genetic Agranulocytosis, Severe Congenital Neutropenia)	51
2.6.1	Caution.	51
2.7	Leukemoid Reaction (LR)	53
2.7.1	Caution.	53
2.8	Granulopoiesis with Increased Eosinophils	54
2.8.1	Caution.	54
2.9	Quantitative and Qualitative Changes in Megakaryocytopoiesis.	57
2.9.1	Morphologic Abnormalities of Megakaryocytes	57
2.9.2	Megakaryocytic Emperipoiesis	57
2.10	Micromegakaryocytes and Hypolobulated/Nonlobulated Megakaryocytes	58
2.11	Enlarged Megakaryocytes with Hyperlobulated Nuclei	61
2.12	Megakaryocytes with Naked Nuclei	62
2.13	Clustering of Megakaryocytes	63
2.13.1	Caution.	63
2.14	Intrasinusoidal Megakaryocytes	66
2.15	Paratrabecular Location of Megakaryocytes	68
2.16	Gray Platelet Syndrome.	70
2.17	Bone Marrow Alterations After Chemotherapy/Stem Cell Transplantation.	72
2.17.1	Caution.	74
2.18	Monoclonal Antibody Treatment (Rituximab).	76
2.18.1	Caution.	76
2.19	Bone Marrow Alterations after Bone Marrow Transplantation	77
2.19.1	Caution.	77
	References.	79
3	Bone Changes Found in Bone Marrow Biopsies	81
	Christine Beham-Schmid	
3.1	Osteodystrophy	81
3.1.1	Renal Osteodystrophy	81
3.1.1.1	Caution	81
3.1.2	Hyperparathyroid Osteodystrophy	83
3.1.2.1	Caution	83
3.1.3	Osteopenia	85
3.1.3.1	Caution	85
3.1.4	Osteomalacia	87
3.1.4.1	Caution	87
3.1.5	Osteopetrosis (Marble Bone Disease)	88
3.1.5.1	Caution	88
3.1.6	Paget's Disease of Bone.	89
3.1.6.1	Caution	89
	References.	90
4	Non-hematological Malignancies in the Bone Marrow	91
	Christine Beham-Schmid	
4.1	Caution.	92
	References.	102
5	Increase of Plasma Cells, Reactive and Neoplastic	103
	Christine Beham-Schmid	
5.1	Reactive Plasmacytosis	103
5.1.1	Caution.	103

5.2	Monoclonal Gammopathy of Undetermined Significance (MGUS)	105
5.2.1	Plasma Cell Myeloma (MM)	105
5.2.2	Epidemiology	105
5.2.3	Morphology	105
5.2.4	Immunohistochemistry	110
5.2.5	Genetic Abnormalities	110
5.2.6	Caution	110
5.3	Plasma Cell Myeloma with Amyloid Deposition	111
5.3.1	Caution	111
	References	113
6	Inflammatory and Infectious Diseases	115
	Christine Beham-Schmid	
6.1	Infectious Diseases	120
6.1.1	Hemophagocytic Syndrome	120
6.1.1.1	Caution	123
6.2	Visceral Leishmaniasis	124
6.2.1	Caution	125
6.3	Parvovirus B19 Infection	126
6.3.1	Caution	127
6.4	Infection with Mycobacterium Tuberculosis	128
	References	130
7	Malignant Lymphomas	131
	Christine Beham-Schmid	
7.1	Introduction	131
7.2	Chronic Lymphocytic Leukemia (CLL)	134
7.2.1	Epidemiology	134
7.2.2	Morphology	134
7.2.3	Transformation of CLL	134
7.2.4	Immunohistochemistry	134
7.2.5	Cytogenetic Abnormalities and Molecular Characteristics	134
7.2.6	Caution	143
7.3	B-Cell Prolymphocytic Leukemia (B-PLL)	144
7.3.1	Epidemiology	144
7.3.2	Morphology	144
7.3.3	Immunohistochemistry	144
7.3.4	Cytogenetic Abnormalities and Molecular Characteristics	144
7.3.5	Caution	147
7.4	Lymphoplasmacytic Lymphoma (LPL)	148
7.4.1	Epidemiology	148
7.4.2	Morphology	148
7.4.3	Immunohistochemistry	148
7.4.4	Cytogenetic Abnormalities and Molecular Characteristics	148
7.4.5	Caution	155
7.5	Mantle Cell Lymphoma (MCL)	156
7.5.1	Epidemiology	156
7.5.2	Morphology	156
7.5.3	Immunohistochemistry	156
7.5.4	Cytogenetic Abnormalities and Molecular Characteristics	156
7.5.5	Caution	159
7.6	Hairy Cell Leukemia (HCL)	162
7.6.1	Epidemiology	162
7.6.2	Morphology	162

7.6.3	Immunohistochemistry	162
7.6.4	Cytogenetic Abnormalities and Molecular Characteristics	162
7.6.5	Caution	168
7.7	Follicular Lymphoma (FL)	169
7.7.1	Epidemiology	169
7.7.2	Morphology	169
7.7.3	Immunohistochemistry	170
7.7.4	Cytogenetic Abnormalities and Molecular Characteristics	170
7.7.5	Caution	172
7.8	Splenic Marginal Zone Lymphoma (SMZL)	173
7.8.1	Epidemiology	173
7.8.2	Morphology	173
7.8.3	Immunohistochemistry	173
7.8.4	Cytogenetic Abnormalities and Molecular Characteristics	173
7.8.5	Caution	177
7.9	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)	178
7.9.1	Epidemiology	178
7.9.2	Morphology	178
7.9.3	Immunohistochemistry	178
7.9.4	Cytogenetic Abnormalities and Molecular Characteristics	178
7.9.5	Caution	182
7.10	Diffuse Large B-Cell Lymphoma (DLBCL)	183
7.10.1	Epidemiology	183
7.10.2	Morphology	183
7.10.3	Immunohistochemistry	183
7.10.4	Cytogenetic Abnormalities and Molecular Characteristics	183
7.10.5	Caution	187
7.11	Intravascular Large B-Cell Lymphoma	188
7.11.1	Caution	188
7.12	Burkitt Lymphoma (BL)	190
7.12.1	Epidemiology	190
7.12.2	Morphology	190
7.12.3	Immunohistochemistry	190
7.12.4	Cytogenetic Abnormalities and Molecular Characteristics	190
7.12.5	Caution	192
7.13	T-Cell Chronic Lymphocytic Leukemia (T-CLL)/T-Cell Prolymphocytic Leukemia (T-PLL)	193
7.13.1	Epidemiology	193
7.13.2	Morphology	193
7.13.3	Immunohistochemistry	193
7.13.4	Cytogenetic Abnormalities and Molecular Characteristics	193
7.13.5	Caution	197
7.14	T-Cell Large Granular Lymphocytic Leukemia (T-LGLL)	198
7.14.1	Epidemiology	198
7.14.2	Morphology	198
7.14.3	Immunohistochemistry	198
7.14.4	Caution	202
7.15	Hepatosplenic T-Cell Lymphoma (HSTL)	203
7.15.1	Epidemiology	203
7.15.2	Morphology	203
7.15.3	Immunohistochemistry	203

7.15.4	Cytogenetic Abnormalities and Molecular Characteristics	203
7.15.5	Caution.	206
7.16	Mycosis Fungoides (MF)/Sezary Syndrome (SS)	207
7.16.1	Epidemiology.	207
7.16.2	Morphology	207
7.16.3	Immunohistochemistry	207
7.16.4	Cytogenetic Abnormalities and Molecular Characteristics	207
7.16.5	Caution.	209
7.17	Peripheral T-Cell Lymphoma, Not Otherwise Specified (PTCL, NOS)	210
7.17.1	Epidemiology.	210
7.17.2	Morphology	210
7.17.3	Immunohistochemistry	210
7.17.4	Cytogenetic Abnormalities and Molecular Characteristics	210
7.17.5	Caution.	212
7.18	Angioimmunoblastic T-Cell Lymphoma (AITL).	213
7.18.1	Epidemiology.	213
7.18.2	Morphology	213
7.18.3	Immunohistochemistry	213
7.18.4	Cytogenetic Abnormalities and Molecular Characteristics	213
7.18.5	Caution.	215
7.19	Anaplastic Large Cell Lymphoma (ALCL)	216
7.19.1	Epidemiology.	216
7.19.2	Morphology	216
7.19.3	Immunohistochemistry	216
7.19.4	Cytogenetic Abnormalities and Molecular Characteristics	216
7.19.5	Caution.	219
7.20	Adult T-Cell Leukemia/Lymphoma (ATLL)	220
7.20.1	Epidemiology.	220
7.20.2	Morphology	220
7.20.3	Immunohistochemistry	220
7.20.4	Cytogenetic Abnormalities and Molecular Characteristics	220
7.21	Hodgkin Lymphoma	223
7.21.1	Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHD).	223
7.21.1.1	Epidemiology	223
7.21.1.2	Morphology.	223
7.21.1.3	Immunohistochemistry	223
7.21.1.4	Cytogenetic Abnormalities and Molecular Characteristics.	223
7.21.1.5	Caution	225
7.22	Classical Hodgkin Lymphoma (cHL)	226
7.22.1	Epidemiology.	226
7.22.2	Morphology	226
7.22.3	Immunohistochemistry	226
7.22.4	Cytogenetic Abnormalities and Molecular Characteristics	226
7.22.5	Caution.	231
	References.	231
8	Mastocytosis.	235
	Annette Schmitt-Graeff	
8.1	Epidemiology and Clinical Features	236
8.2	Morphologic and Immunohistochemical Features of Bone Marrow Involvement by SM	236

8.3	Genetics	237
8.4	Caution	237
	References	251
9	Myeloproliferative Neoplasm (MPN)	253
	Christine Beham-Schmid	
9.1	Introduction	253
9.2	Chronic Myeloid Leukemia (CML), BCR-ABL1-Positive	253
9.2.1	Epidemiology	253
9.2.2	Morphology	253
9.2.3	Chronic Phase (CP)	253
9.2.3.1	Morphologic Findings with TKI Therapy	254
9.2.3.2	Disease Progression of CML	254
9.2.4	Accelerated Phase (AP)	254
9.2.5	Blast Crisis (BC)	254
9.2.6	Immunohistochemistry	255
9.2.7	Genetics	255
9.2.8	Caution	267
9.3	Chronic Neutrophilic Leukemia (CNL)	269
9.3.1	Epidemiology	269
9.3.2	Morphology	269
9.3.3	Immunohistochemistry	269
9.3.4	Genetics	269
9.3.5	Caution	271
9.4	Polycythemia Vera (PV)	272
9.4.1	Epidemiology	272
9.4.2	Morphology	272
9.4.3	“Spent Phase” of PV, Post-polycythemic Myelofibrosis, and Myeloid Metaplasia	272
9.4.4	Caution	274
9.5	Primary Myelofibrosis (PMF)	275
9.5.1	Epidemiology	275
9.5.2	Morphology	275
9.5.3	PMF, Prefibrotic/Early Stage	275
9.5.4	PMF, Overt Fibrotic Stage	278
9.5.5	Immunohistochemistry	278
9.5.6	Caution	280
9.6	Essential Thrombocythemia (ET)	281
9.6.1	Epidemiology	281
9.6.2	Morphology	281
9.6.3	Immunohistochemistry	281
9.6.4	Caution	284
9.7	Myeloproliferative Neoplasm, Unclassifiable (MPN-U)	287
9.7.1	Immunohistochemistry	287
9.7.2	Caution	289
9.8	Monocytoid Progression of MPN and Monocytosis in MPN	290
9.9	Chronic Eosinophilic Leukemia, NOS (CEL-NOS)	292
9.9.1	Epidemiology	292
9.9.2	Morphology	292
9.9.3	Immunohistochemistry and Genetics	292
9.9.4	Caution	294
	References	295

10	Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of <i>PDGFRA</i>, <i>PDGFRB</i>, <i>FGFR1</i>, or with <i>PCMI-JAK2</i>	297
	Annette Schmitt-Graeff	
10.1	Epidemiology and Clinical Features	297
10.2	Morphology	298
10.3	Genetics	298
10.4	Caution	299
	References	309
11	Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)	311
	Annette Schmitt-Graeff	
11.1	Introduction	311
11.2	Chronic Myelomonocytic Leukemia (CMML)	311
11.2.1	Epidemiology	311
11.2.2	Clinical Features	312
11.2.3	Bone Marrow and Blood Findings	312
11.2.4	Immunohistochemistry Applied to BM Trephine Biopsies	312
11.2.5	Molecular Pathogenesis	312
11.2.6	Prognosis	312
11.2.7	Caution	313
11.2.7.1	Transition to AML	313
11.2.7.2	Monocytosis in Classical MPN and Other Myeloid Neoplasms	313
11.2.7.3	Secondary Acquisition of MPN-Typical Genetic and Hematological Features in CMML	313
11.2.7.4	Benign Conditions	313
11.3	Juvenile Myelomonocytic Leukemia (JMML)	325
11.3.1	Epidemiology	325
11.3.2	Clinical and Laboratory Features	325
11.3.3	Morphology	326
11.3.4	Immunohistochemistry	329
11.3.5	Genetics	329
11.3.6	Caution	329
11.3.6.1	Viral infections	329
11.3.6.2	Osteopetrosis	329
11.3.6.3	Noonan Syndrome	330
11.4	Atypical Chronic Myeloid Leukemia, <i>BCR-ABL1</i> -Negative	331
11.4.1	Epidemiology	331
11.4.2	Clinical and Laboratory Features	331
11.4.3	Morphology	331
11.4.4	Immunohistochemistry	331
11.4.5	Genetics	331
11.4.6	Caution	331
11.5	Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (MDS/MPN-U)	334
11.5.1	Epidemiology	334
11.5.2	Clinical and Laboratory Features	334
11.5.3	Morphology	334
11.5.4	Genetics	334
11.5.5	Caution	334

11.6	Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)	337
11.6.1	Epidemiology	337
11.6.2	Morphology	337
11.6.3	Genetics	337
11.6.4	Caution	337
	References	340
12	Myelodysplastic Syndromes (MDS)	343
	Annette Schmitt-Graeff	
12.1	Introduction	343
12.2	Epidemiology	344
12.3	Clinical Features	344
12.4	Morphology and Immunohistochemistry: Dysplasia Assessment in MDS	344
12.4.1	Special Stains in MDS	345
12.4.2	Dysplastic Features Observed in Peripheral Blood and Bone Marrow Specimens	345
12.4.2.1	The Peripheral Blood in MDS	345
12.4.2.2	The Bone Marrow in MDS: Dysplasia Involving the Hematopoietic Lineages	345
12.4.2.3	The Bone Marrow Core Biopsy in MDS: Bone Marrow Architecture and Stromal Components	347
12.5	Genetics in MDS	347
12.5.1	Chromosomal Abnormalities	347
12.5.2	Somatic Mutations	348
12.5.3	Prognostic Relevance of Genetic Alterations in MDS	348
12.5.4	Selected Genetic Profiles Associated with Prognostic Relevance in MDS	348
12.6	Caution	349
	References	380
13	Acute Leukemia of Myeloid, Lymphoid, and Ambiguous Lineage and Related Malignancies	383
	Annette Schmitt-Graeff	
13.1	Introduction	383
13.1.1	Diagnostic Approach to Patients with Suspected AL	383
13.2	Acute Myeloid Leukemia; General Aspects	383
13.2.1	Classification	383
13.2.2	Epidemiology	385
13.2.3	Morphology and Cytochemistry of Blood and Bone Marrow Smears	385
13.2.4	Immunophenotype	385
13.2.5	Genetics	386
13.3	AML with Recurrent Genetic Abnormalities	388
13.3.1	Acute Promyelocytic Leukemia with <i>PML-RARA</i>	388
13.3.1.1	Genetics	388
13.3.1.2	Immunophenotype	388
13.3.1.3	Morphology	388
13.3.1.4	Caution	389

13.3.2	Acute Myelogenous Leukemia (AML) with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2); <i>GATA2</i> ; <i>MECOM</i>	394
13.3.2.1	Genetics	394
13.3.2.2	Immunophenotype	394
13.3.2.3	Morphology	394
13.3.2.4	Caution	394
13.3.3	AML with t(8;21)(q22;q22.1); <i>RUNX1-RUNX1T1</i>	397
13.3.3.1	Genetics	397
13.3.3.2	Immunophenotype	397
13.3.3.3	Morphology	397
13.3.3.4	Caution	397
13.3.4	Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1q22); <i>CBFB-MYH11</i>	402
13.3.4.1	Epidemiology	402
13.3.4.2	Morphology	402
13.3.4.3	Immunophenotype	402
13.3.4.4	Genetics	402
13.3.4.5	Caution	402
13.3.5	Acute Myeloid Leukemia with Translocation t(6;9)(p23;q34.1); <i>DEK-NUP214</i>	408
13.3.5.1	Epidemiology	408
13.3.5.2	Morphology	408
13.3.5.3	Immunophenotype	408
13.3.5.4	Genetics	408
13.3.6	AML with Translocation t(9;11)(p21.3;q23.3); <i>KMT2A-MLL3</i>	411
13.3.6.1	Epidemiology and Clinical Presentation	411
13.3.6.2	Morphology	411
13.3.6.3	Immunophenotype	411
13.3.6.4	Genetics	411
13.3.6.5	Caution	411
13.3.7	AML (Megakaryoblastic) with Translocation t(1;22)(p13.3;q13.1); <i>RBM15-MKLI</i>	416
13.3.7.1	Epidemiology and Clinical Features	416
13.3.7.2	Morphology	416
13.3.7.3	Immunophenotype	416
13.3.7.4	Genetics	416
13.3.7.5	Caution	416
13.3.8	AML with Translocation t(9;22); <i>BCR-ABL1</i>	419
13.3.8.1	Epidemiology and Clinical Features	419
13.3.8.2	Morphology	419
13.3.8.3	Immunophenotype	419
13.3.8.4	Genetics	419
13.3.8.5	Caution	419
13.4	AML with Gene Mutations	422
13.4.1	AML with Mutated <i>NPM1</i>	422
13.4.1.1	Epidemiology and Clinical features	422
13.4.1.2	Morphology	422
13.4.1.3	Immunophenotype	422
13.4.1.4	Genetics	422
13.4.1.5	Caution	422

13.4.2	AML with Biallelic Mutation of <i>CEBPA</i>	429
13.4.2.1	Epidemiology	429
13.4.2.2	Morphology	429
13.4.2.3	Immunophenotype	429
13.4.2.4	Genetics	429
13.4.2.5	Caution	429
13.4.3	AML with Mutated <i>RUNX1</i>	434
13.4.3.1	Epidemiology	434
13.4.3.2	Morphology	434
13.4.3.3	Immunophenotype	434
13.4.3.4	Genetics	434
13.5	AML with Myelodysplasia-Related Changes (AML-MRC)	437
13.5.1	Epidemiology	437
13.5.2	Morphology	437
13.5.3	Immunophenotype	437
13.5.4	Genetics	438
13.5.5	Caution	438
13.6	Therapy-Related Myeloid Neoplasms	442
13.6.1	Epidemiology and Etiology	442
13.6.2	Morphology	442
13.6.3	Immunophenotype	442
13.6.4	Genetics	442
13.7	AML, Not Otherwise Specified	447
13.7.1	AML with Minimal Differentiation	447
13.7.2	AML Without Maturation	450
13.7.3	AML with Maturation	452
13.7.4	Acute Myelomonocytic Leukemia	454
13.7.5	Acute Monoblastic and Monocytic Leukemia	458
13.7.6	Pure Erythroleukemia	461
13.7.6.1	Epidemiology	461
13.7.6.2	Morphology	461
13.7.6.3	Immunophenotype	461
13.7.6.4	Genetics	461
13.7.6.5	Caution	461
13.7.7	Acute Megakaryoblastic Leukemia	467
13.7.7.1	Epidemiology	467
13.7.7.2	Morphology	467
13.7.7.3	Immunophenotype	467
13.7.7.4	Genetics	467
13.7.7.5	Caution	467
13.7.8	Acute Basophilic Leukemia	470
13.7.8.1	Morphology	470
13.7.8.2	Immunophenotype	470
13.7.8.3	Genetics	470
13.7.8.4	Caution	470
13.7.9	Acute Panmyelosis with Myelofibrosis	473
13.7.9.1	Morphology and Immunophenotype	473
13.7.9.2	Genetics	473
13.7.9.3	Caution	473

13.8	Myeloid Sarcoma	476
13.8.1	Epidemiology and Clinical Features	476
13.8.2	Morphology and Immunophenotype	476
13.8.3	Genetics	476
13.8.4	Caution	476
13.9	Myeloid Neoplasms with Germline Predisposition	479
13.9.1	Epidemiology	479
13.9.2	Morphology and Immunophenotype	479
13.9.3	Genetics	479
13.9.4	Caution	479
13.10	Myeloid Proliferations Associated with Down Syndrome	485
13.10.1	Epidemiology and Clinical Findings	485
13.10.2	Morphology and Immunophenotype	485
13.10.3	Genetics	485
13.11	Blastic Plasmacytoid Dendritic Cell Neoplasm	490
13.11.1	Epidemiology and Clinical Features	490
13.11.2	Morphology and Immunophenotype	490
13.11.3	Genetics	490
13.11.4	Caution	490
13.12	Acute Leukemias of Ambiguous Lineage	494
13.12.1	Epidemiology and Clinical Features	494
13.12.2	Morphologic and Immunophenotypic Features	494
13.12.3	Genetics	495
13.12.4	Caution	495
13.13	Precursor Lymphoid Neoplasms: T-Lymphoblastic Leukemia/Lymphoma	499
13.13.1	Epidemiology and Clinical Features	499
13.13.2	Morphology and Immunophenotype	499
13.13.3	Genetics	500
13.13.4	Caution	500
13.14	Precursor Lymphoid Neoplasms: B-Lymphoblastic Leukemia/Lymphoma	513
13.14.1	Epidemiology and Clinical Findings	513
13.14.2	Morphology and Immunophenotype	513
13.14.3	Genetics	514
13.14.4	Caution	514
	References	527

Abbreviations

BBL	Berlin blue iron stain
BCR-ABL	Breakpoint cluster region and Abelson tyrosine kinase
BMB	Bone marrow biopsy
CML	Chronic myeloid leukemia
H&E	Hematoxylin and eosin stain
HPF	High power field
IHC	Immunohistochemistry
ITP	Idiopathic thrombocytopenia
MDS	Myelodysplasia
MGG	May–Grünwald Giemsa stain
MPO	Myeloperoxidase
PCR	Polymerase chain reaction
B-PLL	B-cell prolymphocytic leukemia

1.1 Introduction

Histological investigation of bone marrow biopsy is an integral examination method for diagnosis of various hematological and also non-hematological diseases [1]. Since sampling of bone marrow biopsies (BMB) from newborns as well as geriatric patients can easily be performed, the indications for retrieving BMB have increased, especially in hematology, internal medicine, oncology, but also osteology [2]. Various fixatives and different methods are described for preparation of bone marrow biopsy sections; however, each hematopathologist prefers his own technique used in his laboratory. Therefore, it is not our intention to persuade the investigating pathologists to use a special method, but the need for well-fixed and well-stained thin sections cannot be emphasized enough.

As the name “bone marrow” implies, histological examination includes bone structure as well as marrow. In adults, normal bone marrow consists of fatty tissue and

hematopoiesis, which is present in skull, sternum, clavicle, scapula, vertebrae, ribs, pelvic bone, and proximal sections of hollow bone [3]. The term “marrow cellularity,” used by hematologists and hematopathologists, refers to the actively producing compartment and does not include fatty tissue. Thus, aplastic marrow or hypoplastic marrow shows complete or partial replacement by fat cells. Usually, bone marrow biopsies are taken from the posterior iliac crest [2]. Preferably, bone marrow examination should be done in conjunction with clinical data (including question and/or indication for examination, previous illnesses, drugs) and complete blood count data and, ideally with bone marrow aspirate imprints or smears (in our experience, only in rare cases cytology is available for the investigating hematopathologist; thus, this book focuses on histology, immunohistochemistry and, if necessary, molecular pathological methods of bone marrow biopsies). A bone marrow biopsy containing at least five intertrabecular spaces (excluding subcortical spaces containing mainly fatty tissue) is considered adequate for diagnosis. All biopsy specimens should have sections routinely stained with hematoxylin and eosin (H&E), May–Grünwald Giemsa (MGG) or Giemsa, BBL and reticulin stain (e.g., Gomori’s stain). Metachromatic stains (e.g., MGG) give additional information, which are not available in routinely H&E stained sections. For example, identification of eosinophils, plasma cells, and mast cells is facilitated; furthermore, differentiation of proerythroblasts and myeloblasts is easily possible. Iron stains (e.g., Prussian blue) should be done from each bone marrow biopsy; however, one has to be aware that decalcification might remove iron. Therefore, the report should state “iron stain is negative” and not “there is absence of storage iron.”

The most important and indispensable information for diagnosis of bone marrow biopsies is the knowledge of the patient’s age (without knowledge of the patient’s age, bone marrow diagnosis is not accurate and always incomplete). This knowledge helps to avoid pitfalls in histological

diagnosis, for example, recognition of normally present subcortical hypoplasia or non-representative tangentially retrieved BMB. It is also important to recognize and report changes in hematopoietic cells due to inadequate fixation, decalcification, or staining procedures.

1.1.1 Bone Components (Fig. 1.1)

Representative bone marrow biopsies show cortical bone (cortex, compact bone) and trabecular bone (trabeculae, cancellous bone, ossicles) (Fig. 1.1a, b) with appendant bone




Fig. 1.1 (a, b) Low magnification of representative BMBs with cortical bone (left side) and trabecular bone (left biopsy: Gomori's stain, right biopsy: Ladewig). (c) Higher magnification of (b) showing trabecular bone constituting the honeycomb of bone. (d) Normal bone structure (MGG) of a 50-year-old female. (e) BMB of a 52-year-old

female with rarefaction of trabecular bone (Gomori's stain). (f) A 48-year-old female showing rarefaction of trabecular bone (Gomori's stain). (g) Severely thickened cancellous bone of a 60-year-old male (Gomori's stain). (h) BMB of a 73-year-old male with marked osteosclerosis (Gomori's stain)




Fig. 1.1 (continued)

cells, which are flat endothelial cells, lining trabecular and subcortical surface, osteoblasts, osteoclasts, and osteocytes.

The cortex is a solid layer of compact bone of various thickness, on the outside periosteum, on the inside the endosteum, a single layer of cells, are attached. The cortex mainly consists of lamellar bone, but some woven bone is also present. There is constant remodeling of the bone. In adults, remodeling of the bone mainly takes place in the subcortical regions. A new layer of bone is added by osteoblasts, while the osteoclasts resorb other areas of the bone. Up to 20–25% of the bone surface may be covered by osteoid.

Trabecular bone constitutes the honeycomb of bone (Fig. 1.1c, d) and is enclosed by the cortical bone. A rarefaction of trabeculae (osteopenia) results in enlargement of marrow cavities (Fig. 1.1e, f). A thickening of cancellous bone, osteosclerosis, causes a decreased size of marrow spaces (Fig. 1.1g, h). Semi-automatic and/or computerized quantification systems for bone and bone marrow structures are not generally required for the diagnosis and interpretation of bone marrow biopsy sections. For routine diagnosis, subjective assessment by naked eye of the components of the biopsy sections in a number of fields in the light microscope, or, if requested by the clinicians, assessment by use of a graticule in the ocular is recommended [3] (Fig. 1.2).

Osteoblasts with a diameter from 20 to 50 μm produce the bone matrix, osteoid, which gets subsequently ossified [4]. Osteoblasts line the surface of the cancellous bone and if these cells are activated, they become cuboidal (Fig. 1.2a, b). After mineralization of bone, some osteoblasts are trapped within the bone and transformed into osteocytes (Fig. 1.2c).

The cytoplasmic processes of osteocytes connect with the processes of other osteocytes and also with osteoblasts on the surface of the bone (Fig. 1.2d–f). Thus, a circulatory network within the osseous system, within the bone and to its surface, is built, providing the subsistence of the osteocytes and enables the transfer between bone, bloodstream, and interstitial fluid.

Osteoclasts are the bone-resorbing cells on or near the surface of the bone (Fig. 1.2g), often interposed between endothelial and endosteal cells and also between subcortical bone surface and endothelium on the trabecular surface. Osteoclasts, with their villous extensions bind to matrix adhesion proteins and produce resorption pits, shallow concavities, called Howship lacunae (Fig. 1.2h inset). The appearance of osteoclasts is either uni- or multinuclear. Multinuclear osteoclasts may even become larger than megakaryocytes (Fig. 1.2h). The relatively flat uni-nucleated osteoclasts equally do resorb bone as do the multinucleated forms. Bone marrow biopsies of children and young adults normally show marked bone remodeling with the presence of many osteoclasts, whereas in adults and older people the presence of many osteoclasts indicates a metabolic or a neoplastic disease.

Mean values from healthy adults for osteoblastic index (percentage of trabecular surface covered by cuboidal osteoblasts) is 5%. The osteoclastic index (number of osteoclasts/100 mm trabecular circumference) is 3–4/100 mm [4]. Although osteoclasts and osteoblasts share the surface of the trabeculae (Fig. 1.2g), these cells originate from different stem cells, osteoclasts from hematopoietic, and osteoblasts from mesenchymal stem cells.




Fig. 1.2 (a) Osteoblasts lining the surface of bone (MGG). (b) Cuboidal activated osteoblasts (MGG). (c) Trabecular bone with osteocyte (MGG). (d-f) Cytoplasmic processes of osteocytes connecting with processes of adjacent osteocytes. Inset shows high magnification

of osteocyte (MGG). (g) Multinucleated osteoclast on bone surface (MGG). (h) Huge multinucleated osteoclasts. Inset reveals Howship lacunae (MGG)




Fig. 1.2 (continued)

1.2 Cellularity of the Marrow

While BM aspirates (BMA) and BM trephine biopsies (BMTB) are excellent for assessment of lineage percentages and morphology, only BMTB can provide accurate information about the overall degree of cellularity and organization of all hematopoietic lineages. Also, if lymphocytic cells or plasma cells are increased, only BMTB will reveal the pattern of their distribution.

However, it is important that not only the width of the BMTB is adequate but also the length which ideally should measure at least 2 cm. Length is particularly important not only for the “staging” of neoplasms as to whether there is BM involvement but also in many infectious disease affecting BM (Fig. 1.3).

The term “cellularity” refers to hematopoietic as well as fat cells and indicates the relative amount of these components. Normal values are age-dependent (Fig. 1.3a) with individual deviations [5, 6]. For routine diagnosis, the cellularity is assessed subjectively; otherwise, there is the possibility of computerized image analysis or histomorphometry. Bone marrow cellularity is demonstrated as the percentage of a section occupied by hematopoietic tissue. This percentage can either refer to the entire biopsy including bone tis-

sue, or, similar to an aspirate, to a marrow cavity excluding bone tissue [2]. The latter procedure is comparable to measurements of the cellularity of aspirated fragments. Slight differences in marrow cellularity have been described in different sites like sternum, lumbar vertebrae, and iliac crest [4].

The bone marrow of newborns mainly consists of cells with a negligent amount of fat cells (0–<5%). With increasing age, cellularity decreases with an accelerated rate of reduction beyond the age of 70. The decrease in hematopoietic tissue with advanced age is due to a loss of bone substance and also caused by a true loss of the amount of hematopoietic tissue. The marrow cavities consequently are filled with fat cells. At the age of 20, the average cellularity is 70–80%, at the age of 50 cellularity is 50–60%, and at 70 years and beyond, cellularity is reduced to 20–30% [2, 6–8] (Fig. 1.3a).

The spatial arrangement of hematopoiesis is a potential pitfall with regard to the normally present subcortical hypoplasia (subcortical fatty tissue) (Fig. 1.3b–d). To avoid the error of estimating cellularity in subcortical regions, it is necessary to pay attention to bone structures in the biopsy (e.g., a tangentially taken sample with plenty of cortical bone Fig. 1.3e). A representative biopsy (as mentioned before) should show at least three intertrabecular spaces [9, 10].




Fig. 1.3 (a) Schematic representation of cellularity in normal bone marrow biopsies showing decrease of hematopoiesis with advanced age. (b) BMB of a patient with myeloproliferative neoplasm (left side is representative for diagnosis, the biopsy on the right side reveals subcor-

tical fatty tissue) (MGG). (c, d) Physiological subcortical hypoplasia: a common diagnostic pitfall (MGG). (e) The whole length of the biopsy shows cortical bone (tangentially taken sample) (MGG)

1.2.1 Topography (Fig. 1.4)

In the marrow cavities, hematopoietic tissue is distributed interstitial in the extravascular compartment (between the sinusoids) (Fig. 1.4a, b). In some pathological conditions, hematopoiesis can be found intrasinusoidal also. Myeloid precursor cells are closely attached to the endosteal surface and arterioles (Fig. 1.4c–f), more mature granulopoietic cells are seen in central intertrabecular areas. Attention should be paid to the term “myeloid,” which, in the German- and English-speaking parts, has two different meanings. On the

one hand, “myeloid” implies the complete hematopoiesis, on the other hand this term describes the granulopoietic and monocytopenoietic lineage only, as demonstrated by the myeloid: erythroid (M:E) ratio. Usually, there is no interpretation problem, but ambiguousness in using the term “myeloid” should be avoided.

Groups of erythropoietic cells and megakaryocytes show a close association to the marrow sinusoids [3, 5, 8] (Fig. 1.4g, h). In normal bone marrow, considerable variations in the qualitative as well as quantitative distribution of cellular components can be observed.




Fig. 1.4 (a, b) Distribution of hematopoiesis in the extravascular compartment (MGG). (c, d) Myeloid precursors are located closely to the surface of bone trabeculae (MGG). (e, f) Myeloid precursors located

around arterioles (MGG). (g) Erythropoietic island closely attached to sinus (MGG). (h) Close association of megakaryocyte to sinus (MGG)




Fig. 1.4 (continued)

1.3 Cellular Components of the Bone Marrow

1.3.1 Hematopoiesis

Hematopoiesis occurs in the extravascular marrow spaces in a well-arranged order [11]. A common stem cell gives rise to all types of myeloid and lymphoid cells. Morphologically, the pluripotent stem cells and the stem cells committed to the specific cell lineages cannot be identified. For a healthy hematopoiesis, an efficient microenvironment is essential to provide all factors necessary for differentiation, proliferation, and maturation of stem cells to committed lineages. This environment mainly consists of adipocytes, macrophages, endothelial cells, bone lining cells, and extracellular matrix [12]. The normal values in the peripheral blood are reflected by the hematopoietic cells in the bone marrow. Hematopoiesis is rather sensitive to external influences. Proliferation occurs especially in neoplastic disease, suppression often is seen in chronic inflammation, malnutrition, toxic, or drug-induced conditions [13, 14].

Hematopoiesis in the elderly shows changes relating to physiological immunodeficiency as a result of aging with the occasional occurrence of dyshematopoiesis [15].

1.3.2 Erythrocytopoiesis (Fig. 1.5)

The nucleated precursors of the red cells are arranged in islands of various size comprising stages of maturation from the earliest recognizable erythroblast to the normoblast.

These erythroblastic islands, called erythrone, usually enclose a centrally located macrophage. This macrophage (called “mother cell”) often contains nuclear or cellular debris or hemosiderin (Fig. 1.5a). Usually, the red cells closely attached to the macrophage are more immature than the cells in the periphery. However, probably due to the plane of sectioning, the classical form of an erythropoietic island with centrally located macrophage is rarely found in biopsy sections. Normally, erythropoietic islands are located closely to marrow sinusoids (Fig. 1.5b–d). The normal myeloid: erythroid ratio in the BMB is 1.5:1 to 3:1. The early forms of nucleated red cells are large with small cytoplasm and large, rather round nuclei with dispersed chromatin and detectable nucleoli, which are occasionally adjoining the nuclear membrane. These early forms express both transferrin and glycophorin. More mature red cells show a rather condensed chromatin. With maturation, erythropoietic cells lose transferrin expression, while the expression of glycophorin remains stable [16] (Fig. 1.5e, f).

The following features are helpful in distinguishing erythroid precursors from other myeloid cells in the normal BMB: (1) occurrence of erythroid precursors normally in the form of clusters (islands) with cells of various maturation stage (2) usually, erythroblasts are closely attached to one another, (3) the nuclei are rather round, (4) late erythroblasts show regularly condensed chromatin, and lymphocytes (with a similar size) show a coarsely granular clumping of chromatin, (5) localization of erythrone is typically close to sinusoids [12, 17–19]. Since proerythroblasts and normoblasts are highly mitotically active cells, these cells show the highest amount of proliferation rate in normal BMBs (Fig. 1.5g, h).




Fig. 1.5 (a) Erythron with enclosed macrophage (mother cell) containing hemosiderin (Prussian blue). (b–d) Erythropoietic islands are normally situated close to sinusoids (MGG). (e, f) Comparison of transferrin expression and glycophorin C expression in the same area of biopsy (left side: stained with antibody to transferrin [CD71], right side

shows staining with antibody to Glycophorin C). (g, h) Normal BMB of older patient stained with H&E. On the right side, the same biopsy is immunohistochemically stained with the proliferation marker Ki67: Erythropoietic cells show the highest proliferation fraction




Fig. 1.5 (continued)

1.3.3 Granulocytopoiesis (Figs. 1.6 and 1.7)

Sections of normal BMBs contain neutrophils, eosinophils, and basophils, which can be identified by metachromatic stains (e.g., MGG) or immunohistochemically (Fig. 1.6a, b). The granulocytopoiesis, representing 50–70% of nucleated cells, quantitatively dominates the hematopoiesis. According to maturation, myeloblasts, promyelocytes, myelocytes, metamyelocytes, and segmented forms can be detected. The most immature myeloid cell detectable in bone marrow sections is the myeloblast, mostly located closely attached to the trabecular surface, or periarteriolar (Fig. 1.6c, d). In greater number promyelocytes and myelocytes are seen, which, in thin stained sections show a granulation of the cytoplasm. These cells are located also in the generation zone of myeloid cells. The more mature granulopoietic cells do not show any connections with the paratrabeular or periarteriolar areas. The distribution of granulopoietic cells can be highlighted immunohistochemically with antibodies to myeloperoxidase (MPO) and CD15. MPO shows a strong positivity in promy-

elocytes, and a rather weak positivity in more mature forms (Fig. 1.6e, f), whereas CD15 is strongly positive in metamyelocytes and granulocytes (Fig. 1.7a–d) [19]. Neutrophils and eosinophils are easily detectable in conventionally stained sections; however, for the detection of basophilic differentiated cells, special stains, or immunohistochemical investigations are necessary.

If the myeloid:erythroid ratio is increased without decrease in erythroid cells, granulocytic hyperplasia is indicated. In such conditions, either normal proportions of the various maturation stages are seen, or there can be a “shift to the left” with preponderance of immature forms, or a “shift to the right” with an increase of mature granulocytes. As mentioned before, the paratrabeular and periarteriolar areas constitute the generation zones of granulopoietic cells, more mature forms are seen in central areas of marrow spaces. However, single immature granulopoietic cells are found without recognizable connection to paratrabeular or periarteriolar areas. Normally, since granulocytopoiesis is very effective, all cells produced reach the circulation [4].




Fig. 1.6 (a) Eosinophils are easily identified with MGG. (b) A few basophils are detected in normal bone marrow immunohistochemically (2D7). (c, d) Myeloid precursors located peritrabeular (left biopsy)

and periarteriolar (right side) (MGG). (e, f) Strong positivity of precursor myeloid cells using an antibody to MPO